Sunday, April 27

Pharmacology Education Division Programming: Addressing prescribing errors through medical student education and assessment
San Diego Convention Center, Room 5B
3:00 PM – 5:30 PM

Chairs: Senthil K. Rajasekaran, Eastern Virginia Med. Sch. and David W. Nierenberg, Dartmouth-Hitchcock Med. Ctr.

Medication errors are estimated to cost $37 billion and result in 7,000 annual deaths, with a majority of these errors due to improper dosing, wrong drug, or wrong duration. However, in most medical schools, pharmacology training is limited to the early basic science years. The ability to prescribe commonly used drugs safely and effectively should be a core competency of the newly qualified doctor. Given that prescribing is such a fundamental part of medical practice, it is important to develop appropriate and acceptable curricula and assessments to ensure that medical students are gaining these skills before they graduate and move on to their PGY I positions. This symposium will give the audience an opportunity to learn about such an assessment tool created in the UK and will provide tools to implement a curriculum to teach this competency to medical students.

Education in safe and effective prescribing practices
David W. Nierenberg, Dartmouth-Hitchcock Med. Center
 
Assessing prescribing competence of senior medical students: A UK perspective
Simon Maxwell, Univ. of Edinburgh
 
A four-year longitudinal curricular model to teach prescribing skills to medical students
Senthil K. Rajasekaran, Eastern Virginia Med. Sch.



Monday, April 28

B.B. BRODIE AWARD LECTURE IN DRUG METABOLISM
San Diego Convention Center, Room 5A
2:00 PM – 2:50 PM
Bruce D. Hammock, Univ. of California-Davis
Epoxide Hydrolases in Drug Metabolism and as Drug Targets

 

P.B. DEWS AWARD LECTURE IN BEHAVIORAL PHARMACOLOGY
San Diego Convention Center, Room 4
2:00 PM – 2:50 PM
James H. Woods, Univ. of Michigan Sch. of Med.
The Stimulus Functions of Drugs
 

Behavioral Pharmacology Division Symposium: Making the right choice: Translational use of choice procedures in understanding the neurobiology and development of pharmacotherapies for drug addiction
San Diego Convention Center, Room 4
3:00 PM – 5:30 PM

Chairs: Matthew L. Banks, Virginia Commonwealth Univ. and Michael A. Nader, Wake Forest Univ.

Choice procedures are perhaps the most homologous model in which to study behavior. Although choice procedures are almost exclusively used in human laboratory studies of substance abuse, there is a small but growing body of literature in both rodent and nonhuman primate models of substance abuse that are employing choice porcedures. This symposium will discuss the utility of choice procedures to provide insight into novel biological targets and potential pharmacological strategies for substance abuse. The discussions will involve theoretical considerations, experimental design issues for studies involving humans and animals, and how this baseline can inform researchers about the neurobiology and pharmacology of drug abuse. 

Gender difference in drug vs. food choice behaviors
Tod Kippin, Univ. of California – Santa Barbara

The use of choice procedures to understand drug mixtures
Kevin Freeman, Univ. of Mississippi Med. Center

Utility of choice procedures for medication development for drug dependence in preclinical studies
Matthew L. Banks, Virginia Commonwealth Univ.

Utility of choice procedures in human drug abuse laboratory studies
William W. Stoops, Univ of Kentucky Coll. of Med.

Psychophysiological prediction of drug choice
Scott J. Moeller, Icahn Sch. of Med. at Mount Sinai

Drug Metabolism Division James Gillette Award and Platform Session
San Diego Convention Center, Room 5A
3:00 PM – 5:30 PM
Chairs: Jeffrey P. Jones, Washington State Univ. and Larry C. Wienkers, Amgen Inc. 



CYP3A5 genotype impacts maraviroc pharmacokinetics in healthy volunteers
Yanhui Lu, Johns Hopkins Univ.

Application of physiologically-based pharmacokinetic modeling in hepatic impairment populations
Jennifer E. Sager, Univ. of Washington

Gestational age-dependent maternal-fetal glyburide disposition in pregnant mice
Diane L. Shuster, Univ. of Washington

The orally active male contraceptive agent H2-gamendazole interacts with Organic Anion Transporting Polypeptides (OATPs) expressed in human hepatocytes
Jessica Shoop, Univ. of Kansas Med. Ctr.

The potent inhibition of human SULT1A1 by 17β-ethinylestradiol (EE2) is due to interactions with ILE89 in loop 1
Katie Jo Rohn-Glowacki, Univ. of Alabama at Birmingham

Intracellular chloride concentration and its impact on dichloroacetate metabolism
Stephan Jahn, Univ. of Florida

James Gillette Best Paper Award: Genetic variation in aldo-keto reductase 1D1 (AKR1D1) affects the expression and activity of multiple cytochrome P450s
Amarjit S. Chaudhry, St. Jude Children's Research Hosp.

James Gillette Best Paper Award: Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazolebased on the inhibition of the hepatic update transporter and metabolic enzymes
Toshiyuki Kudo, Musashino Univ. 

Molecular Pharmacology Division Postdoctoral Award Finalists
San Diego Convention Center, Room 5B
3:00 PM – 5:30 PM
Keynote Speaker: Richard A. Heyman, Seragon Pharmaceuticals

Alveolar type II cell-localized p120-catenin is an essential regulator of lung barrier function and innate immunity
Andreia Chignalia, Univ. of Illinois at Chicago

G protein-coupled receptor kinase selective small molecule inhibitors
Kristoff Homan, Univ. of Michigan

GPCRs and heterotrimeric G proteins directly regulate member type-1 matrix metalloprotease
Aaron Overland, Univ. of California at San Diego

Keynote Address: Nuclear receptors: Integrating molecular endocrinology and drug discovery
Richard A. Heyman, Seragon Pharmaceuticals

Neuropharmacology Division Postdoctoral Scientist Award Finalists
San Diego Convention Center, Room 2
3:00 PM – 5:30 PM
Keynote Speaker: Athina Markou, Univ. of California at San Diego



Characterization of the kappa opioid receptor-mediated G protein signaling in mouse striatum using [35S]GTPγS binding assay
Lei Zhou, The Scripps Research Inst.

Analysis of functional selectivity at the nociception opioid receptor
Steven Chang, Washington Univ. in St. Louis

VTA GABA(A) receptors mediate maladaptive disinhibition of dopamine release in the NAc — a potential mechanism for increased risk taking behavior following adolescent voluntary alcohol intake
Abigail Schindler, Univ. of Washington

μ opioid receptor activity is regulated by endothelin converting enzyme-2
Erin Bobeck, Icahn Med. Sch. at Mt. Sinai

Identification of a novel, highly potent D3 dopamine receptor-selective agonist
Amy Moritz, NINDS, NIH

Influence of M1 muscarinic acetylcholine receptor activation on arousal and cognitive performance using electroencephalography and novel touchscreen cognition assessment
Robert Gould, Vanderbilt Univ.

Keynote address: Glutamate and nictoine dependence: The route to medication development with advise from Chiron, the centaur
Athina Markou, Univ. of California at San Diego

Behavioral Pharmacology and Neuropharmacology Divisions Joint Mixer
Marriott Marquis & Marina, Point Loma
6:45 PM – 8:45 PM 

Drug Metabolism and Toxicology Divisions Joint Mixer
Marriott Marquis & Marina, Chicago/Atlanta
7:30 PM – 9:30 PM

Molecular Pharmacology Division Mixer
Marriott Marquis & Marina, Marriott Hall I
7:30 PM – 9:30 PM 

Pharmacology Education, Drug Discovery and Development, & Integrative Systems, Translational and Clinical Pharmacology Divisions Joint Mixer
Marriott Marquis & Marina, New York
7:30 PM – 9:30 PM

Back to Top 



Tuesday, April 29

Cardiovascular Pharmacology Division Trainee Showcase
San Diego Convention Center, Room 3
2:30 PM – 4:30 PM
Chair: Amy C. Arnold, Vanderbilt Univ.

Membrane cholesterol and caveolar modulation of cardiac function, ischemic tolerance and opioidergic protection
Louise See Hoe, Griffith Univ.

Contribution of guanine nucleotide exchange factor Vav2 to homocysteine-induced NLRP3 inflammasome activation in mouse podocytes
Justine Abais, Virginia Commonwealth Univ.

PSD95 scaffolding of the Shaker-type K+ channel enables PKA-dependent phosphorylation and vasodilation of cerebral arteries
Christopher Moore, Univ. of Arkansas for Med. Sci.

Short-term Toll-like receptor 9 stimulation increases blood pressure and vascular dysfunction via attenuated NO and exacerbated ROS generation
Cameron McCarthy, Georgia Regents Univ.

New insights on endothelial CaMKII in angiotensin II-induced hypertension
Chimene Charbel, Univ. de Montréal

Mitochondrial processing peptidases as a target therapy for vascular endothelial dysfunction in atherosclerosis
Deepesh Pandey, Johns Hopkins Univ.

Novel roles of chromogranin A and its peptide, catestatin, in cardioprotection
Jan Schilling, Univ. of California at San Diego

Drug Discovery and Development Division Symposium: Productive public private partnerships for pharmacological progress
San Diego Convention Center, Room 4
3:00 PM – 5:30 PM

Chair: John S. Lazo, Univ. of Virginia 

Introduction to public private partnerships
John S. Lazo, Univ. of Virginia 

The role of the NCATS in fostering public-private partnerships in translation 
Christopher P. Austin, Natl. Ctr. for Advancing Translational Sci. (NCATS), NIH 

We have to work together to catalyse the discovery of new medicines
Chas Bountra, Univ. of Oxford 

Pfizer's strategies to access external innovation through partnerships with academia
Robert Abraham, Pfizer Pharmaceuticals 

Allosteric modulators of GPCRs as a novel approach to treatment of CNS disorders
Carrie K. Jones, Vanderbilt Univ. Med. Sch. 

Integrative Systems, Translational and Clinical Pharmacology Division Young Investigator Awards Platform Session
San Diego Convention Center, Room 5A
3:00 PM – 5:30 PM
Chairs: Michael A. Holinstat, Thomas Jefferson Univ. and Ross Corriden, Univ. of California at San Diego

Introduction 

Evidence for an angiotensin-(1-7) neuropeptidase in the brain medulla of sheep
Allyson Marshall, Wake Forest Univ. Sch. of Med.

Effect of HIV-1 Tat on enteric neuropathogenesis
Joy Ngwainmbi, Virginia Commonwealth Univ.

Enhanced in vitro cancer cell cytotoxicity of dual ligand-targeted liposomes
Shravan Sriraman, CPBN, Northeastern Univ.

Effects of selective inhibitors of the isoprenoid biosynthetic pathway on androgen-dependent and independent prostate cancer cells
Jacqueline Reilly, Univ. of Iowa

Targeting GUCY2C for anti-obesity pharmacotherapy
Gilbert Kim, Thomas Jefferson Univ.

Rgs16 is an early marker of pancreatic ductal adenocarcinoma
Ozhan Ocal, UT Southwestern Med. Ctr.

PAR4 Mediates an Elevated Risk for Thrombosis in Blacks Relative to Whites
Benjamin Tourdot, Thomas Jefferson Univ.

Toxicology Division Symposium: Macrophages and tissue injury: Agents of defense or destruction?
San Diego Convention Center, Room 5B
3:00 PM – 5:30 PM

Chair: Debra L. Laskin, Rutgers Univ. 

Pathologic and protective role of macrophages in drug-induced hepatotoxicity
Debra L. Laskin, Rutgers Univ.

Macrophage subpopulations in kidney injury and repair
Jeremy S. Duffield, Univ. of Washington

Macrophage heterogeneity in cardiovascular disease
Filip K. Swirski, Mass General Hosp./Harvard Med. Sch.

Macrophages are required to maintain type 2-dependent inflammation, immunity, and fibrosis
Luke Barron, NIH/NIAID

PAUL M. VANHOUTTE AWARD LECTURE IN VASCULAR PHARMACOLOGY
San Diego Convention Center, Room 3
4:30 PM – 5:30 PM
Sue P. Duckles, Univ. of California-Irvine Col. of Med.
Vascular Mysteries: More than the Sum of the Part
 

Cardiovascular Pharmacology Division Mixer
Marriott Marquis & Marina, Presidio I/II
6:30 PM – 8:00 PM

Back to Top 



Wednesday, April 30

RAY FULLER AWARD LECTURE
San Diego Convention Center, Room 2
8:30 AM – 9:20 AM
Jeffrey M. Witkin, Lilly Research Labs
AMPA receptor potentiation: Implications for the discovery of medicines for treatment-resistant depression
 

RAY FULLER SYMPOSIUM: Treatment-resistant depression (TRD): Biological bases and treatments
San Diego Convention Center, Room 2
9:30 AM – 12:00 PM
Chair: Jeffrey M. Witkin, Lilly Research Labs 

The Ray Fuller symposium will complement the Ray Fuller Lecture by addressing new approaches to attacking the problem of treatment resistance depression by focusing on both novel clinical approaches as well as new developments in preclinical modeling.
 

Introduction
Jeffrey M. Witkin, Lilly Research Labs

Neurostimulation
Paul E. Holtzhiemer, Dartmouth Hitchcock Med. Ctr.

The glutamate hypothesis
Phil Skolnick, NIDA

The cholinergic hypothesis
Christian C. Felder, Lilly Research Labs

Kappa opioid receptors
Irwin Lucki, Univ. of Pennsylvania

Back to Top 

Back to Program